December 5, 2025Open Access

Targeting ubiquitin-specific protease 14 reduces metastatic potential and metabolic activity in cervical cancer via direct modulation of monocarboxylate transporter-4

LMLakshay MalhotraUniversity of Delhi AGAshna GuptaDR. B.R.A. Institute Rotary Cancer Hospital ASAnju SurendranathSidra Medical and Research Center

Key Points

Targeting USP14 reduces tumor growth in cervical cancer, while also disrupting metabolic processes.
The study identifies monocarboxylate transporter-4 as a key player in USP14-mediated metabolic reprogramming.
This research proposes an innovative approach that targets the USP14-MCT4 axis as a therapeutic strategy.
Findings highlight the importance of understanding the oncogenic pathways in cervical cancer for future treatments.

Abstract

This study uncovers MCT4 as a novel substrate of USP14, linking USP14 activity to metabolic reprogramming in CC. The USP14-MCT4 axis represents a previously unrecognized oncogenic pathway with therapeutic potential. Targeting USP14 could simultaneously impair tumor growth and disrupt lactate metabolism, offering a promising strategy for CC treatment.

Ask AI

Helpful

Bookmark

View Full Paper